Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 31 | 2023 | 1578 | 3.070 |
Why?
|
| Alzheimer Disease | 33 | 2024 | 2144 | 3.020 |
Why?
|
| Cognitive Dysfunction | 17 | 2024 | 1073 | 2.100 |
Why?
|
| Hospitalization | 5 | 2019 | 323 | 1.710 |
Why?
|
| Cognition | 21 | 2024 | 1378 | 1.600 |
Why?
|
| Dementia | 11 | 2024 | 582 | 1.550 |
Why?
|
| Aged, 80 and over | 55 | 2024 | 4901 | 1.550 |
Why?
|
| Health Literacy | 7 | 2018 | 109 | 1.460 |
Why?
|
| Independent Living | 12 | 2022 | 320 | 1.310 |
Why?
|
| Aged | 59 | 2024 | 9343 | 1.240 |
Why?
|
| Female | 62 | 2024 | 15818 | 1.080 |
Why?
|
| Male | 62 | 2024 | 15399 | 1.040 |
Why?
|
| Activities of Daily Living | 10 | 2022 | 612 | 1.030 |
Why?
|
| Cohort Studies | 20 | 2024 | 1942 | 0.910 |
Why?
|
| Humans | 76 | 2024 | 28548 | 0.890 |
Why?
|
| Decision Making | 12 | 2016 | 229 | 0.870 |
Why?
|
| Brain | 15 | 2024 | 1696 | 0.860 |
Why?
|
| Economics | 3 | 2018 | 18 | 0.830 |
Why?
|
| DNA-Binding Proteins | 5 | 2022 | 274 | 0.740 |
Why?
|
| Longitudinal Studies | 17 | 2023 | 1397 | 0.730 |
Why?
|
| Work | 1 | 2020 | 8 | 0.720 |
Why?
|
| Social Behavior | 2 | 2011 | 72 | 0.720 |
Why?
|
| Women | 1 | 2020 | 14 | 0.710 |
Why?
|
| TDP-43 Proteinopathies | 2 | 2021 | 110 | 0.640 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2019 | 17 | 0.630 |
Why?
|
| Emergencies | 1 | 2019 | 36 | 0.620 |
Why?
|
| Social Participation | 2 | 2022 | 12 | 0.560 |
Why?
|
| Interpersonal Relations | 3 | 2014 | 104 | 0.550 |
Why?
|
| Cognition Disorders | 5 | 2016 | 1019 | 0.550 |
Why?
|
| Neuropsychological Tests | 15 | 2021 | 1255 | 0.550 |
Why?
|
| Information Literacy | 2 | 2014 | 9 | 0.550 |
Why?
|
| Biomarkers | 2 | 2020 | 601 | 0.540 |
Why?
|
| Risk Assessment | 1 | 2019 | 676 | 0.510 |
Why?
|
| United States | 9 | 2024 | 2188 | 0.500 |
Why?
|
| Motor Activity | 3 | 2013 | 330 | 0.490 |
Why?
|
| Delay Discounting | 1 | 2015 | 25 | 0.470 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 46 | 0.470 |
Why?
|
| Social Environment | 2 | 2011 | 83 | 0.450 |
Why?
|
| Trust | 1 | 2014 | 13 | 0.450 |
Why?
|
| Fraud | 1 | 2014 | 21 | 0.440 |
Why?
|
| Caregivers | 10 | 2008 | 203 | 0.430 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 185 | 0.420 |
Why?
|
| Mental Health | 2 | 2014 | 123 | 0.420 |
Why?
|
| Age Factors | 8 | 2020 | 789 | 0.410 |
Why?
|
| Medicare | 4 | 2024 | 121 | 0.400 |
Why?
|
| Educational Status | 6 | 2020 | 297 | 0.390 |
Why?
|
| Association | 1 | 2011 | 7 | 0.390 |
Why?
|
| Mobility Limitation | 2 | 2012 | 95 | 0.370 |
Why?
|
| Lewy Body Disease | 1 | 2012 | 100 | 0.370 |
Why?
|
| Cerebral Infarction | 1 | 2012 | 150 | 0.360 |
Why?
|
| Diet, Mediterranean | 2 | 2023 | 101 | 0.350 |
Why?
|
| Risk | 4 | 2015 | 207 | 0.340 |
Why?
|
| Risk Factors | 10 | 2022 | 2414 | 0.340 |
Why?
|
| Loneliness | 3 | 2023 | 63 | 0.310 |
Why?
|
| Residence Characteristics | 5 | 2016 | 214 | 0.300 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 1863 | 0.300 |
Why?
|
| Memory | 6 | 2018 | 311 | 0.300 |
Why?
|
| Middle Aged | 18 | 2019 | 9320 | 0.290 |
Why?
|
| Prospective Studies | 6 | 2019 | 1811 | 0.290 |
Why?
|
| Sex Factors | 7 | 2020 | 477 | 0.280 |
Why?
|
| Autopsy | 5 | 2021 | 346 | 0.280 |
Why?
|
| Apolipoprotein E4 | 4 | 2022 | 264 | 0.280 |
Why?
|
| Brain Infarction | 2 | 2018 | 75 | 0.270 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 352 | 0.250 |
Why?
|
| Quality of Life | 3 | 2012 | 659 | 0.250 |
Why?
|
| Mental Competency | 4 | 2008 | 10 | 0.250 |
Why?
|
| Social Isolation | 2 | 2023 | 30 | 0.240 |
Why?
|
| Mental Status and Dementia Tests | 3 | 2020 | 70 | 0.240 |
Why?
|
| Chicago | 7 | 2021 | 942 | 0.230 |
Why?
|
| Apolipoproteins E | 3 | 2023 | 253 | 0.230 |
Why?
|
| Genotype | 2 | 2018 | 359 | 0.230 |
Why?
|
| Income | 3 | 2022 | 78 | 0.220 |
Why?
|
| Family | 2 | 2020 | 115 | 0.220 |
Why?
|
| Amyloid beta-Peptides | 5 | 2024 | 327 | 0.210 |
Why?
|
| Neuroimaging | 2 | 2021 | 133 | 0.200 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2016 | 327 | 0.190 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2022 | 22 | 0.190 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 239 | 0.190 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 183 | 0.190 |
Why?
|
| Disease Progression | 4 | 2020 | 722 | 0.180 |
Why?
|
| Politics | 3 | 2008 | 11 | 0.180 |
Why?
|
| Patient Participation | 4 | 2008 | 53 | 0.180 |
Why?
|
| Depression | 3 | 2015 | 454 | 0.180 |
Why?
|
| Financing, Personal | 3 | 2018 | 20 | 0.180 |
Why?
|
| Social Segregation | 1 | 2020 | 7 | 0.180 |
Why?
|
| Cognitive Reserve | 1 | 2021 | 39 | 0.170 |
Why?
|
| Employment | 1 | 2020 | 43 | 0.170 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 934 | 0.170 |
Why?
|
| Personality | 1 | 2021 | 56 | 0.170 |
Why?
|
| Brain Diseases | 1 | 2021 | 67 | 0.170 |
Why?
|
| Arteriolosclerosis | 2 | 2021 | 78 | 0.170 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 309 | 0.170 |
Why?
|
| Awareness | 1 | 2020 | 45 | 0.170 |
Why?
|
| Cognitive Aging | 1 | 2020 | 79 | 0.160 |
Why?
|
| Memory Disorders | 1 | 2020 | 171 | 0.160 |
Why?
|
| Disability Evaluation | 2 | 2011 | 291 | 0.160 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 6 | 0.150 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 8 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 392 | 0.150 |
Why?
|
| Models, Neurological | 1 | 2018 | 25 | 0.150 |
Why?
|
| Research Subjects | 2 | 2008 | 11 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 45 | 0.150 |
Why?
|
| Blood Glucose | 1 | 2018 | 108 | 0.150 |
Why?
|
| Mutation | 1 | 2020 | 352 | 0.150 |
Why?
|
| Neural Pathways | 1 | 2018 | 73 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 121 | 0.150 |
Why?
|
| Neurofibrillary Tangles | 4 | 2022 | 194 | 0.150 |
Why?
|
| Regression Analysis | 2 | 2015 | 270 | 0.140 |
Why?
|
| White Matter | 2 | 2016 | 142 | 0.140 |
Why?
|
| Learning | 2 | 2016 | 71 | 0.140 |
Why?
|
| Prevalence | 2 | 2012 | 467 | 0.140 |
Why?
|
| Hospital Mortality | 1 | 2018 | 148 | 0.140 |
Why?
|
| Stress, Psychological | 2 | 2016 | 242 | 0.140 |
Why?
|
| Exercise | 1 | 2021 | 472 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 133 | 0.140 |
Why?
|
| Informed Consent | 2 | 2008 | 22 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2017 | 74 | 0.140 |
Why?
|
| Sepsis | 1 | 2018 | 144 | 0.130 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2016 | 12 | 0.130 |
Why?
|
| RNA Splicing | 1 | 2016 | 10 | 0.130 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2016 | 17 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 191 | 0.130 |
Why?
|
| Intelligence | 1 | 2016 | 21 | 0.130 |
Why?
|
| Adult | 6 | 2022 | 8172 | 0.130 |
Why?
|
| Interview, Psychological | 2 | 2008 | 42 | 0.130 |
Why?
|
| Gray Matter | 1 | 2016 | 55 | 0.130 |
Why?
|
| Comprehension | 1 | 2016 | 32 | 0.130 |
Why?
|
| Incidence | 3 | 2016 | 774 | 0.130 |
Why?
|
| Alleles | 2 | 2018 | 221 | 0.120 |
Why?
|
| Crime Victims | 1 | 2016 | 33 | 0.120 |
Why?
|
| Amyloid | 3 | 2021 | 57 | 0.120 |
Why?
|
| Health Behavior | 2 | 2014 | 165 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2017 | 442 | 0.120 |
Why?
|
| Psychological Tests | 1 | 2015 | 53 | 0.120 |
Why?
|
| Time Factors | 3 | 2014 | 1497 | 0.120 |
Why?
|
| Racism | 1 | 2015 | 32 | 0.110 |
Why?
|
| Poverty | 1 | 2015 | 100 | 0.110 |
Why?
|
| Music | 1 | 2014 | 24 | 0.110 |
Why?
|
| Multilingualism | 1 | 2014 | 21 | 0.110 |
Why?
|
| Minority Groups | 1 | 2015 | 87 | 0.110 |
Why?
|
| Neoplasms | 1 | 2017 | 241 | 0.110 |
Why?
|
| tau Proteins | 3 | 2022 | 235 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 180 | 0.110 |
Why?
|
| Social Support | 2 | 2015 | 215 | 0.110 |
Why?
|
| Odds Ratio | 4 | 2018 | 269 | 0.110 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 227 | 0.110 |
Why?
|
| Neprilysin | 1 | 2012 | 11 | 0.100 |
Why?
|
| Automobile Driving | 1 | 2012 | 20 | 0.100 |
Why?
|
| Actigraphy | 1 | 2012 | 101 | 0.100 |
Why?
|
| Disabled Persons | 1 | 2013 | 125 | 0.090 |
Why?
|
| Lewy Bodies | 3 | 2018 | 194 | 0.090 |
Why?
|
| Muscle Strength | 1 | 2012 | 138 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2011 | 44 | 0.090 |
Why?
|
| Environmental Health | 1 | 2010 | 8 | 0.090 |
Why?
|
| Motor Skills Disorders | 1 | 2010 | 16 | 0.090 |
Why?
|
| Health Status | 2 | 2012 | 226 | 0.090 |
Why?
|
| Phobic Disorders | 1 | 2010 | 66 | 0.090 |
Why?
|
| Urban Population | 1 | 2011 | 158 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2005 | 990 | 0.080 |
Why?
|
| Third-Party Consent | 1 | 2008 | 1 | 0.080 |
Why?
|
| Ethics, Research | 1 | 2008 | 3 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2011 | 467 | 0.070 |
Why?
|
| Assisted Living Facilities | 1 | 2008 | 6 | 0.070 |
Why?
|
| Attitude | 1 | 2008 | 36 | 0.070 |
Why?
|
| Nursing Homes | 1 | 2008 | 37 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 58 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1213 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2015 | 154 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 61 | 0.070 |
Why?
|
| Selegiline | 1 | 2005 | 4 | 0.060 |
Why?
|
| alpha-Tocopherol | 1 | 2005 | 13 | 0.060 |
Why?
|
| Mood Disorders | 1 | 2005 | 31 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2018 | 599 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2005 | 43 | 0.060 |
Why?
|
| Civil Rights | 1 | 2004 | 3 | 0.060 |
Why?
|
| Self Report | 2 | 2016 | 226 | 0.060 |
Why?
|
| Healthy Lifestyle | 1 | 2024 | 46 | 0.050 |
Why?
|
| Illinois | 2 | 2015 | 248 | 0.050 |
Why?
|
| Statistics as Topic | 2 | 2015 | 112 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 21 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 41 | 0.050 |
Why?
|
| Unconsciousness | 1 | 2022 | 9 | 0.050 |
Why?
|
| Infarction | 1 | 2022 | 30 | 0.050 |
Why?
|
| Anthocyanins | 1 | 2022 | 11 | 0.050 |
Why?
|
| Sclerosis | 1 | 2022 | 66 | 0.050 |
Why?
|
| Fruit | 1 | 2022 | 26 | 0.050 |
Why?
|
| Logistic Models | 2 | 2018 | 398 | 0.050 |
Why?
|
| Motor Skills | 1 | 2021 | 53 | 0.050 |
Why?
|
| Individuality | 1 | 2021 | 25 | 0.050 |
Why?
|
| Neuroticism | 1 | 2021 | 32 | 0.050 |
Why?
|
| Southeastern United States | 1 | 2020 | 14 | 0.040 |
Why?
|
| Midwestern United States | 1 | 2020 | 62 | 0.040 |
Why?
|
| Religion | 1 | 2019 | 42 | 0.040 |
Why?
|
| Multilevel Analysis | 1 | 2018 | 7 | 0.040 |
Why?
|
| Heterozygote | 1 | 2018 | 102 | 0.040 |
Why?
|
| Neuropathology | 1 | 2018 | 84 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 283 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2017 | 27 | 0.030 |
Why?
|
| Mental Status Schedule | 2 | 2008 | 97 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 330 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 28 | 0.030 |
Why?
|
| Plaque, Amyloid | 1 | 2017 | 146 | 0.030 |
Why?
|
| Critical Care | 1 | 2018 | 199 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2016 | 83 | 0.030 |
Why?
|
| Anisotropy | 1 | 2016 | 53 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2016 | 87 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 1197 | 0.030 |
Why?
|
| Diagnosis | 1 | 2015 | 24 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 75 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 228 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 16 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 96 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 74 | 0.030 |
Why?
|
| Cities | 1 | 2015 | 17 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 190 | 0.030 |
Why?
|
| Financial Management | 1 | 2015 | 24 | 0.030 |
Why?
|
| Life Change Events | 1 | 2014 | 38 | 0.030 |
Why?
|
| Memory, Episodic | 1 | 2016 | 116 | 0.030 |
Why?
|
| Empathy | 1 | 2014 | 46 | 0.030 |
Why?
|
| Mental Recall | 1 | 2014 | 71 | 0.030 |
Why?
|
| Language | 1 | 2014 | 69 | 0.030 |
Why?
|
| Spouses | 2 | 2005 | 27 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 623 | 0.030 |
Why?
|
| Spatial Behavior | 1 | 2012 | 9 | 0.030 |
Why?
|
| Licensure | 1 | 2012 | 9 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2012 | 23 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 23 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 16 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 24 | 0.020 |
Why?
|
| Environment | 1 | 2012 | 47 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 121 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 56 | 0.020 |
Why?
|
| Mice | 1 | 2016 | 1467 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 276 | 0.020 |
Why?
|
| Baltimore | 1 | 2011 | 9 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 255 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 310 | 0.020 |
Why?
|
| Reaction Time | 1 | 2011 | 114 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 98 | 0.020 |
Why?
|
| Executive Function | 1 | 2011 | 116 | 0.020 |
Why?
|
| Psychometrics | 1 | 2011 | 244 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 213 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 356 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2008 | 111 | 0.020 |
Why?
|
| Observer Variation | 1 | 2008 | 104 | 0.020 |
Why?
|
| Simvastatin | 1 | 2008 | 14 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 145 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 3814 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 827 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 3622 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 520 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 329 | 0.020 |
Why?
|
| Professional-Family Relations | 1 | 2005 | 26 | 0.020 |
Why?
|
| Judgment | 1 | 2005 | 9 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2005 | 53 | 0.020 |
Why?
|
| Nootropic Agents | 1 | 2005 | 15 | 0.020 |
Why?
|
| Policy Making | 1 | 2004 | 14 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2004 | 58 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2005 | 166 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 146 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2003 | 139 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2002 | 7 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2002 | 97 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 732 | 0.010 |
Why?
|